Keyword: Onyx Pharmaceuticals



When Amgen agreed to nab Onyx for $10.4 billion back in 2013, multiple myeloma drug Kyprolis—central to the deal—was on a tear. After generating $64 million in its first partial year on the market, it had nearly doubled that tally with $125 million in the first few months of 2013.